Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical Industries

Drug Profile

Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical Industries

Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; Allogeneic STRO-3 immunoselected bone marrow-derived mesenchymal precursor cells (MPCs) - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-25-Osteo; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanson Institute; Institute of Medical and Veterinary Science
  • Developer Angioblast Systems; Mesoblast; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Heart failure; Hodgkin's disease; Intervertebral disc degeneration; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
  • Phase I/II Diabetic nephropathies
  • No development reported Age-related macular degeneration; Fracture; Lung disorders; Peripheral arterial disorders; Skin ulcer

Most Recent Events

  • 17 Oct 2018 Mesoblast Limited and Tasly Pharmaceutical completes transaction for strategic cardiovascular partnership in China
  • 17 Jul 2018 Mesoblast and Tasly Pharmaceutical enter into an alliance for the development, manufacture and commercialisation of Rexlemestrocel-L in China for Chronic heart failure and Myocardial infarction
  • 28 Apr 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Australia (Intraocular, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top